PEXIVAS challenges current ANCA-associated vasculitis therapy
- PMID: 32203311
- DOI: 10.1038/s41581-020-0269-6
PEXIVAS challenges current ANCA-associated vasculitis therapy
Comment on
-
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.N Engl J Med. 2020 Feb 13;382(7):622-631. doi: 10.1056/NEJMoa1803537. N Engl J Med. 2020. PMID: 32053298 Free PMC article. Clinical Trial.
References
-
- Robson, J. et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology 54, 471–481 (2015). - DOI
-
- Walsh, M. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622–631 (2020). - DOI
-
- Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955–963 (2002). - DOI
-
- Jayne, D. R. W. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180–2188 (2007). - DOI
-
- Walsh, M. et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 84, 397–402 (2013). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
